Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Cancer Neuroscience: Crossing Disciplines to Revolutionize Cancer Treatment

Award Number: R13CA306203
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/21/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2026

Group Awards By:

View Award Description

Cancer Neuroscience: Crossing Disciplines to Revolutionize Cancer Treatment - Accelerated understanding of nervous system functions and cancer has led to cancer neuroscience evolving into a new frontier of discovery in cancer biology and therapy. The 3rd Cancer Neuroscience: Crossing Disciplines to Revolutionize Cancer Treatment biennial symposium. It will build on the remarkable success of our previous meetings, which attracted over 2,400 participants from 70 countries and resulted in high-impact publications in Advanced Biology (2022) and Cancer Cell (2024). Survey results of past symposia have indicated overwhelming satisfaction with the meeting and have consistently identified a critical, unmet need for the field: increased understanding of neuro-immune interactions in cancer. The 2026 meeting will address this by making neuroimmuno-oncology its centerpiece at a time when both immunotherapy and neuromodulation are demonstrating unprecedented clinical potential. This focus reflects the symposium's commitment to remaining responsive to participant feedback while driving forward cutting-edge research at the nexus of these disciplines. Building on our track record of fostering cross-disciplinary dialogue, we will create a platform that brings together oncologists, neuroscientists, immunologists, cancer biologists, and a wide array of other disciplines. The program will feature keynote sessions on neural regulation of anti-tumor immunity, in both central and peripheral nervous systems, pioneering research on neuro-immune crosstalk in the tumor microenvironment, and translation of findings to clinical applications that address healthcare disparities for marginalized populations. Our overall goal is to accelerate advances in cancer neuroscience by facilitating dialogue between established leaders while nurturing a new generation of scientists. We aim to 1) advance understanding of neuroimmune interactions in cancer through cross-disciplinary integration; 2) support early-career investigators through mentorship and career development; and 3) Accelerate scientific discovery through strategic cross-institutional collaboration. This meeting comes at a critical time when understanding neural regulation of cancer immunity could transform treatment. The Cancer Neuroscience Symposium will catalyze discoveries at the intersection of neurobiology, immunology, and cancer biology. By breaking down the barriers that have separated these fields, we will ultimately improve outcomes for all patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2027 ( Subtotal = -$12 )
2027	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	1	10/20/2026	NEW	-$12
														Subtotal = -$12

Issue Date FY: 2025 ( Subtotal = $10,000 )
2025	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	1	8/20/2025	NEW	$10,000
														Subtotal = $10,000

Grand Total All Awards = $9,988

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cancer Neuroscience: Crossing Disciplines to Revolutionize Cancer Treatment

Award Number: R13CA306203

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/21/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer